Marianne De Backer, Vir Biotechnology CEO
June 5, 2024 05:57 AM EDTUpdated 09:48 AM
R&D

Vir's ear­ly Phase 2 he­pati­tis D da­ta show re­duc­tion, re­moval of virus with com­bo and monother­a­py

Katherine Lewin

News Reporter

Vir’s chron­ic he­pati­tis D treat­ment re­duced the pres­ence of the virus RNA as well as nor­mal­ized cer­tain liv­er en­zyme lev­els across 24 weeks in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times